Human Cord Blood Transplantation

Title:   UARK 2006-28: Human Cord Blood Transplantation in Advanced Hematological Malignancies 
Sponsor:  UAMS MIRT 
PI:  Frits van Rhee, MD, PhD 
Phase:  II 
Purpose:   The researchers on this study want to find out if subjects treated on this study will acheive long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment. The researchers also want to find out what types, if any, of side effects subjects will experience with this treatment. 
Eligibility:   You are being asked to take part in this research study because you have an active hematological malignancy that requires treatment. Up to 10 subjects, male or female, age 18 or older, regardless of race or ethnicity, with advanced hematological malignancies are anticipated to be enrolled locally in this study. UAMS will be the only center where this study will be performed. 
Treatment:  You will be admitted to the hospital and receive standard conditioning chemotherapy that is not part of this study, but is determined by your physician and required to participate in this study. Approximately, 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood which is the reason for this study. Prior to and/or following the transfusion of human cord blood you will receive drugs into your vein (cyclosporine and mycophenolate) to prevent the human cord blood from rejecting or reacting to your body. This reaction is called Graft-vs-Host disease (GVHD). During the time your immune system is very low, you will also be supported with UAMS standard of care blood products and treatment to prevent infection or other complications. These drugs are not part of the present study. 
Contact:  Nathan Perry
Phone: 501-526-6990 ext. 2435